Allergen immunotherapy for pediatric asthma: current evidence and knowledge gaps.
Age Factors
Allergens
/ administration & dosage
Allergy and Immunology
/ standards
Asthma
/ diagnosis
Biomarkers
/ analysis
Child
Clinical Trials as Topic
Desensitization, Immunologic
/ methods
Humans
Meta-Analysis as Topic
Monitoring, Immunologic
/ methods
Practice Guidelines as Topic
Prognosis
Systematic Reviews as Topic
Time Factors
Time-to-Treatment
/ standards
Treatment Outcome
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
pubmed:
24
1
2020
medline:
16
6
2021
entrez:
24
1
2020
Statut:
ppublish
Résumé
The introduction of high-quality and standardized extracts for immunotherapy has renewed the interest in the treatment of pediatric allergic asthma that represents a high-prevalence disease. In addition to clinical trials, several systematic reviews and metaanalyses were published, confirming overall the clinical efficacy of allergen immunotherapy in pediatric asthma. In addition, new data on the preventive effect of the treatment on asthma onset were published. Despite this, many intriguing questions emerged, in parallel to the development of knowledge. Allergen immunotherapy is overall effective for the treatment of asthma in children, but a class-effect should not be claimed, rather the efficacy of each single product. According to the recent findings, the challenge for the future research will be to clarify: when to start immunotherapy in children, which are (if they exist) the predictive biomarkers for efficacy in the single individual, the magnitude of the preventive effect and the optimal duration of the treatment.
Identifiants
pubmed: 31972602
doi: 10.1097/ACI.0000000000000618
pii: 00130832-202004000-00013
doi:
Substances chimiques
Allergens
0
Biomarkers
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
162-167Références
Global Initiative for the Management of Asthma, 2018. www.ginasthma.org (last accessed February 2019).
Oksel C, Custovic A. Development of allergic sensitization and its relevance to paedatric asthma. Curr Opin Allergy Clin Immunol 2018; 18:109–116.
Comberiati P, Di Cicco ME, D’Elios S, Peroni DG. How much asthma is atopic in children? Front Pediatr 2017; 5:122.
Schoos AM, Jelding-Dannemand E, Stokholm J, et al. Single and multiple time-point allergic sensitization during childhood and risk of asthma by age 13. Pediatr Allergy Immunol 2019; 30:716–723.
De Ferrari L, Chiappori A, Bagnasco D, et al. Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma? Expert Rev Respir Med 2016; 10:29–38.
Shamji MH, Durham SR. Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J Allergy Clin Immunol 2017; 140:1485–1498.
Satitsuksanoa P, van de Veen W, Akdis M. B-cell responses in allergen immunotherapy. Curr Opin Allergy Clin Immunol 2019; 19:632–639.
Comberiati P, Marseglia GL, Barberi S, et al. Allergen-specific immunotherapy for respiratory allergy in children: unmet needs and future goals. J Allergy Clin Immunol Pract 2017; 5:946–950.
Penagos M, Passalacqua G, Compalati E, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008; 133:599–609.
Roberts G, Hurley C, Turcanu V, Lack G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol 2006; 117:263–268.
Alzakar RH, Alsamarai AM. Efficacy of immunotherapy for treatment of allergic asthma in children. Allergy Asthma Proc 2010; 31:324–330.
Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009; 123:167–173.
Bahçeciler NN, Işik U, Barlan IB, Başaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001; 32:49–55.
Niu CK, Chen WY, Huang JL, et al. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multicenter, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med 2006; 100:1374–1383.
Lue KH, Lin YH, Sun HL, et al. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol 2006; 17:408–415.
Pham-Thi N, Scheinmann P, Fadel R, et al. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol 2007; 18:47–57.
de Bot CM, Moed H, Berger MY. Et Sublingual immunotherapy not effective in house dust mite-allergic children in primary care. Pediatr Allergy Immunol 2012; 23:150–158.
Stelmach I, Kaczmarek-Woźniak J, Majak P, et al. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Clin Exp Allergy 2009; 39:401–408.
Yukselen A, Kendirli SG, Yilmaz M, et al. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. Int Arch Allergy Immunol 2012; 157:288–298.
Eifan AO, Akkoc T, Yildiz A, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy 2010; 40:922–932.
Keles S, Karakoc-Aydiner E, Ozen A, et al. A novel approach in allergen specific immunotherapy: combination of sublingual and subcutaneous routes. J Allergy Clin Immunol 2011; 128:808–811.
Rice JL, Diette GB, Suarez-Cuervo C, et al. Allergen-specific immunotherapy in the treatment of pediatric asthma: a systematic review. Pediatrics 2018; 141: doi: 10.1542/peds.2017-3833.
doi: 10.1542/peds.2017-3833
Dhami S, Kakourou A, Asamoah F, et al. Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis. Allergy 2017; 72:1825–1848.
Liao W, Hu Q, Shen LL, et al. Sublingual immunotherapy for asthmatic children sensitized to house dust mite: a metaanalysis. Medicine 2015; 94:1–14.
Richards JL, Stumpf JR. House dust mite sublingual immunotherapy for pediatric patients with allergic asthma. Ann Pharmacother 2018; 52:1019–1030.
Rodríguez Del Río P, Vidal C, Vidal C, et al. The European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a paediatric assessment. Pediatr Allergy Immunol 2017; 28:60–70.
Passalacqua G, Nowak-Węgrzyn A, Canonica GW. Local side effects of sublingual and oral immunotherapy. J Allergy Clin Immunol Pract 2017; 5:13–21.
Agostinis F, Tellarini L, Canonica GW, et al. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy 2005; 60:133.
Fiocchi A, Pajno G, La Grutta S, et al. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann Allergy Asthma Immunol 2005; 95:254–258.
Arasi S, Passalacqua G, Caminiti L, et al. Efficacy and safety of sublingual immunotherapy in children. Expert Rev Clin Immunol 2016; 12:49–56.
Johnstone DE, Dutton A. The value of hyposensitization therapy for bronchial asthma in children: a 14-year study. Pediatrics 1968; 42:793–802.
Moller C, Dreborg S, Ferdousi HA, et al. Immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT study). J Allergy Clin Immunol 2002; 109:251–256.
Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004; 114:851–857.
Marogna M, Tomassetti D, Bernasconi A, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol 2008; 101:206–211.
Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62:943–948.
Valovirta E, Petersen TH, Piotrowska T, et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol 2018; 141:529–538.
Zielen S, Devillier P, Heinrich J, et al. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real-word database analysis. Allergy 2018; 73:165–177.
Kristiansen M, Dhami S, Netuveli G, et al. Allergen immunotherapy for the prevention of allergy: a systematic review and meta-analysis. Pediatr Allergy Immunol 2017; 28:18–29.
Di Bona D, Plaia A, Leto-Barone MS, et al. Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review. Allergy 2017; 72:691–704.
Halken S, Larenas-Linnemann D, Roberts G, et al. EAACI guidelines on allergen immunotherapy: prevention of allergy. Pediatr Allergy Immunol 2017; 28:728–745.
Wahn U. Preventing new sensitization and asthma onset by allergen immunotherapy: the current evidence. Curr Opin Allergy Clin Immunol 2017; 17:443–446.
Holt PG, Sly PD, Sampson HA, et al. Prophylactic use of sublingual allergen immunotherapy in high-risk children: a pilot study. J Allergy Clin Immunol 2013; 132:991–993.
Zolkipli Z, Roberts G, Cornelius V, et al. Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood. J Allergy Clin Immunol 2015; 136:1541–1547.
Asamoah F, Kakourou A, Dhami S, et al. Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews. Clin Transl Allergy 2017; 7:25.
Dinakar C, Chipps BE. Clinical tools to assess asthma control in children. Pediatrics 2017; 139:e20163438.
Larenas-Linnemann D, Luna-Pech JA. What you should not miss from the systematic reviews and meta-analyses on allergen-specific immunotherapy in 2017. Curr Opin Allergy Clin Immunol 2018; 18:168–176.
Bachert C, Larché M, Bonini S, et al. Allergen immunotherapy on the way to product-based evaluation: a WAO statement. World Allergy Organ J 2015; 8:2.
Agache I, Lau S, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: house dust mite-driven allergic asthma. Allergy 2019; 74:855–873.
Scadding GW, Eifan AO, Lao-Araya M, et al. Effect of grass pollen immunotherapy on clinical and local immune response to nasal allergen challenge. Allergy 2015; 70:689–696.
Arroabarren E, Tabar AI, Echechipía S, et al. Optimal duration of allergen immunotherapy in children with dust mite respiratory allergy. Pediatr Allergy Immunol 2015; 26:34–41.
Pajno GB, Bernardini R, Peroni D, et al. Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report. Ital J Pediatr 2017; 43:13.
Tosca MA, Licari A, Olcese R, et al. Immunotherapy and asthma in children. Front Pediatr 2018; 6:231.
Tortajada-Girbés M, Mesa Del Castillo M, Larramona H, et al. Decision-making for pediatric allergy immunotherapy for aeroallergens: a narrative review. Eur J Pediatr 2019; 178:1801–1812.
Canonica GW, Ansotegui IJ, Pawankar R, et al. A WAO–ARIA–GA2LEN consensus document on molecular-based allergy diagnostics. World Allergy Organ J 2013; 6:17.
Melioli G, Savi E, Crivellaro MA, Passalacqua G. Potential of molecular based diagnostics and its impact on allergen immunotherapy. Asthma Res Pract 2016; 2:9.
Martínez-Cañavate Burgos A, Torres-Borrego J, Molina Terán AB, et al. Molecular sensitization patterns and influence of molecular diagnosis in immunotherapy prescription in children sensitized to both grass and olive pollen. Pediatr Allergy Immunol 2018; 29:369–374.
Stringari G, Tripodi S, Caffarelli C, et al. The effect of component-resolved diagnosis on specific immunotherapy prescription in children with hay fever. J Allergy Clin Immunol 2014; 134:75–81.
Matricardi PM, Dramburg S, Potapova E, et al. Molecular diagnosis for allergen immunotherapy. J Allergy Clin Immunol 2019; 143:831–843.
Li JT, Bernstein DI, Calderon MA, et al. Sublingual grass and ragweed immunotherapy: clinical considerations: a PRACTALL consensus report. J Allergy Clin Immunol 2016; 137:369–376.
European Medicines Agency. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. CHMP/EWP/18504/2006, European Medicines Agency. http://emea.europa.eu (last accessed November 20, 2008).
Rose K, Kopp MV. Pediatric investigation plans for specific immunotherapy: questionable contributions to childhood health. Pediatr Allergy Immunol 2015; 26:695–701.
Sindher SB, Long A, Acharya S, et al. The use of biomarkers to predict aero-allergen and food immunotherapy responses. Clin Rev Allergy Immunol 2018; 55:190–204.